Immunoregulatory role of TNFα in inflammatory kidney diseases

被引:125
作者
Ernandez, Thomas [1 ,2 ]
Mayadas, Tanya N. [1 ,2 ]
机构
[1] Harvard Univ, Sch Med, Boston, MA 02115 USA
[2] Brigham & Womens Hosp, Ctr Excellence Vasc Biol, Dept Pathol, Boston, MA 02115 USA
关键词
autoimmunity; glomerulonephritis; kidney inflammation; TNF alpha; TNF receptors; vasculitis; TUMOR-NECROSIS-FACTOR; SYSTEMIC-LUPUS-ERYTHEMATOSUS; CYTOKINE GENE POLYMORPHISMS; NF-KAPPA-B; RAT MESANGIAL CELLS; EXPERIMENTAL CRESCENTIC GLOMERULONEPHRITIS; SINGLE NUCLEOTIDE POLYMORPHISMS; FACTOR SOLUBLE RECEPTORS; ACTIVE CROHNS-DISEASE; MHC CLASS-II;
D O I
10.1038/ki.2009.142
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Tumor necrosis factor alpha (TNF alpha), a pleiotropic cytokine, plays important inflammatory roles in renal diseases such as lupus nephritis, anti-neutrophil cytoplasmic antibody (ANCA)-associated glomerulonephritis and renal allograft rejection. However, TNF alpha also plays critical immunoregulatory roles that are required to maintain immune homeostasis. These complex biological functions of TNF alpha are orchestrated by its two receptors, TNFR1 and TNFR2. For example, TNFR2 promotes leukocyte infiltration and tissue injury in an animal model of immune complex-mediated glomerulonephritis. On the other hand, TNFR1 plays an immunoregulatory function in a murine lupus model with a deficiency in this receptor that leads to more severe autoimmune symptoms. In humans, proinflammatory and immunoregulatory roles for TNF alpha are strikingly illustrated in patients on anti-TNF alpha medications: These treatments are greatly beneficial in certain inflammatory diseases such as rheumatoid arthritis but, on the other hand, are also associated with the induction of autoimmune lupus-like syndromes and enhanced autoimmunity in multiple sclerosis patients. The indication for anti-TNF alpha treatments in renal inflammatory diseases is still under discussion. Ongoing clinical trials may help to clarify the potential benefit of such treatments in lupus nephritis and ANCA-associated glomerulonephritis. Overall, the complex biology of TNF alpha is not fully understood. A greater understanding of the function of its receptors may provide a framework to understand its contrasting proinflammatory and immunoregulatory functions. This may lead the development of new, more specific anti-inflammatory drugs. Kidney International (2009) 76, 262-276; doi:10.1038/ki.2009.142; published online 13 May 2009
引用
收藏
页码:262 / 276
页数:15
相关论文
共 226 条
[1]   TNFR1-and TNFR2-mediated signaling pathways in human kidney are cell type-specific and differentially contribute to renal injury [J].
Al-Lamki, RS ;
Wang, J ;
Vandenabeele, P ;
Bradley, JA ;
Thiru, S ;
Luo, DH ;
Min, W ;
Pober, JS ;
Bradley, JR .
FASEB JOURNAL, 2005, 19 (12) :1637-1645
[2]   Expression of tumor necrosis factor receptors in normal kidney and rejecting renal transplants [J].
Al-Lamki, RS ;
Wang, J ;
Skepper, JN ;
Thiru, S ;
Pober, JS ;
Bradley, JR .
LABORATORY INVESTIGATION, 2001, 81 (11) :1503-1515
[3]   Cytokine gene polymorphisms and risks of acute rejection and delayed graft function after kidney transplantation [J].
Alakulppi, NS ;
Kyllönen, LE ;
Jäntti, VT ;
Matinlauri, IH ;
Partanen, J ;
Salmela, KT ;
Laine, JT .
TRANSPLANTATION, 2004, 78 (10) :1422-1428
[4]   A murine transmembrane tumor necrosis factor (TNF) transgene induces arthritis by cooperative p55/p75 TNF receptor signaling [J].
Alexopoulou, L ;
Pasparakis, M ;
Kollias, G .
EUROPEAN JOURNAL OF IMMUNOLOGY, 1997, 27 (10) :2588-2592
[5]  
[Anonymous], 1999, Neurology, V53, P457
[6]   Safety and efficacy of tumor necrosis factor α blockade in systemic lupus erythematosus -: An open-label study [J].
Aringer, M ;
Graninger, WB ;
Steiner, GN ;
Smolen, JS .
ARTHRITIS AND RHEUMATISM, 2004, 50 (10) :3161-3169
[7]  
ARINGER M, 2006, DOUBLE BLIND RANDOMI
[8]   The role of tumor necrosis factor-alpha in systemic lupus erythematosus [J].
Aringer, Martin ;
Smolen, Josef S. .
ARTHRITIS RESEARCH & THERAPY, 2008, 10 (01)
[9]   Effects of short-term infliximab therapy on autoantibodies in systemic lupus erythematosus [J].
Aringer, Martin ;
Steiner, Guenter ;
Graninger, Winfried B. ;
Hoefler, Elisabeth ;
Steiner, Carl W. ;
Smolen, Josef S. .
ARTHRITIS AND RHEUMATISM, 2007, 56 (01) :274-279
[10]   Haematopoietic malignancies in rheumatoid arthritis:: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists [J].
Askling, J ;
Fored, CM ;
Baecklund, E ;
Brandt, L ;
Backlin, C ;
Ekbom, A ;
Sundström, C ;
Bertilsson, L ;
Cöster, L ;
Geborek, P ;
Jacobsson, LT ;
Lindblad, S ;
Lysholm, J ;
Rantapää-Dahlqvist, S ;
Saxne, T ;
Klareskog, L ;
Feltelius, N .
ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 (10) :1414-1420